Stay updated on Pembrolizumab for Biliary Tract Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Biliary Tract Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Biliary Tract Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an increase in the progression-free survival rate at 6 months from 60% to 75% in patients with biliary tract cancer treated with a combination of standard chemotherapy and pembrolizumab.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:06.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the required health conditions and prior treatments for inclusion in the study. Previously, this section had no information provided.
    Difference
    43%
    Check dated 2024-05-22T21:23:07.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:25:16.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Biliary Tract Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Biliary Tract Cancer Clinical Trial page.